Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006149/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



CSL

Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful
Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220307005938/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



CSL

Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent
Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220302006217/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



CSL

Neue Behandlungsoption für Patienten mit SHPT – Rayaldee® in der Schweiz ab sofort verfügbar
Neue Behandlungsoption für Patienten mit SHPT – Rayaldee® in der Schweiz ab sofort verfügbar


Vifor Pharma Schweiz AG gab heute die Markteinführung des Calcifediol-Retardpräparats Rayaldee® in der Schweiz bekannt. Rayaldee® ist die erste und einzige in Europa zugelassene orale Therapie

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220227005069/en/



Vifor Fresenius Medical Care Renal Pharma (VFMCRP)

Vifor Pharma reports sustained growth in 2021
Vifor Pharma reports sustained growth in 2021


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Pharma Group reported a solid performance in 2021 and an increase in profitability, supported by a strong recovery in Ferinject

Vifor Pharma Gruppe erzielt nachhaltiges Wachstum in 2021
Vifor Pharma Gruppe erzielt nachhaltiges Wachstum in 2021


Regulatory News:



AD HOC-MITTEILUNG GEMÄSS ART. 53 KR



Die Vifor Pharma Gruppe verzeichnete 2021 eine solide Geschäftsentwicklung und eine Steigerung der Profitabilität, die von einer starken

Vifor Pharma gibt Markteinführung von Tavneos® in Deutschland bekannt
Vifor Pharma gibt Markteinführung von Tavneos® in Deutschland bekannt


Vifor Pharma Deutschland GmbH hat heute die Markteinführung von Tavneos® bekannt gegeben, der ersten in Europa zugelassenen oralen Therapie für die Behandlung der beiden Haupttypen von

Vifor Pharma appoints two new members to the Executive Committee
Vifor Pharma appoints two new members to the Executive Committee


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Pharma Group today announced the appointment of acting Chief Financial Officer Alexandros Sigalas and Group General Counsel Dr

VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis
VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis


Regulatory News:



Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Commission has approved Tavneos® in combination with a rituximab or cyclophosphamide regimen

CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.
CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005418/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



CSL

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with

Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005059/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor

Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005992/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor

CSL Limited announces tender offer to acquire Vifor Pharma Ltd
CSL Limited announces tender offer to acquire Vifor Pharma Ltd


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global

GeNeuro erhält von der Schweizer Regierung Finanzmittel in Höhe von 6,7 Millionen Schweizer Franken (6,4 Millionen Euro) für die Entwicklung von Temelimab gegen Long COVID
GeNeuro erhält von der Schweizer Regierung Finanzmittel in Höhe von 6,7 Millionen Schweizer Franken (6,4 Millionen Euro) für die Entwicklung von Temelimab gegen Long COVID


GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), ein biopharmazeutisches Unternehmen, das neue Therapien für neurodegenerative und Autoimmunerkrankungen entwickelt, meldete heute, dass

Vifor Pharma comments on media speculation
Vifor Pharma comments on media speculation


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this

Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID
Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID


Regulatory News:



GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final

First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease


Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult

Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor

Vifor Pharma comments on market speculations
Vifor Pharma comments on market speculations


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Due to current market speculations, Vifor Pharma Group states the following:



Vifor Pharma Group systematically reviews options that

Vifor Pharma announces changes to the Executive Committee as CFO retires
Vifor Pharma announces changes to the Executive Committee as CFO retires


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Pharma Group today announced that Colin Bond, Chief Financial Officer will retire from the company by the end of December 2021

Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the  Society for Inherited Metabolic Disorders Annual Meeting
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
DGAP-News: BB Biotech AG concludes its share buyback program and launches a new buyback program
DGAP-News: BB Biotech AG concludes its share buyback program and launches a new buyback program
DGAP-News: BB Biotech AG concludes its share buyback program and launches a new buyback program